NCT06868758View on ClinicalTrials.gov

Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer

Active, not recruitingOBSERVATIONAL

Enrollment

50

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

HER2 Positive Breast CarcinomaNeoadjuvant Therapy

Trial Locations (1)

401121

Chongqing General Hospital, Chongqing

All Listed Sponsors

lead

Chongqing General Hospital

OTHER